ViiV Healthcare shared pipeline and real-world data | CROI 2026

ViiV Healthcare shared an extensive program of data presentations at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI), taking place in Denver, Colorado, from Feb. 22 to 25, 2026.

The company presented new clinical and early-stage pipeline data on long-acting and ultra-long-acting HIV treatment and prevention, including the first-in-human results for VH184 and early findings for VH499, according to a news release.

“We are making major advances towards new ultra-long-acting regimens that build on ViiV’s legacy of integrase inhibitors, including pipeline assets such as VH184 that have the potential to extend dosing intervals to four months or longer – beyond what is available today for HIV treatment,” Jean van Wyk, MBChB, chief medical officer at ViiV Healthcare, said in the news release. “Listening to the needs of the HIV community shapes our research and development, and the breadth of clinical and real‑world data we are presenting at CROI 2026 reflects our commitment to delivering long-acting therapies that people impacted by HIV need and want.”

At CROI 2026, ViiV highlighted progress across its integrase strand transfer inhibitor (INSTI)-led pipeline, including first-in-human data for long-acting injectable formulations of VH184. As the first third-generation INSTI in development, VH184 is designed with the potential to enable dosing intervals of four months or longer. Data from the ongoing phase I study provided important insights into pharmacokinetics, safety and tolerability, alongside an in vitro resistance analysis comparing VH184 with bictegravir.

The company also shared early clinical data supporting the development of VH499, an investigational injectable HIV capsid inhibitor. Presentations included an analysis informing dose selection and the feasibility of ultra-long-acting regimens.

In addition, an interim 12-month analysis from the phase IIb EMBRACE study evaluated lotivibart (N6LS), an investigational broadly neutralizing antibody administered every four months, in combination with monthly long-acting cabotegravir. The data assessed long-term viral suppression and safety, further exploring the potential of antibody-based combinations to support extended dosing intervals.

CROI 2026 will also feature new clinical data and real-world evidence from ViiV’s established long-acting and two-drug regimens, including Cabenuva (cabotegravir + rilpivirine long-acting), the first complete long-acting injectable regimen for HIV treatment, and Dovato (dolutegravir/lamivudine). Insights from these studies further informed long-term outcomes, treatment satisfaction and implementation in diverse care settings.

Cabenuva continues to generate evidence supporting its effectiveness and real-world uptake. Meanwhile, Dovato remains central to ViiV’s strategy of reducing drug exposure while maintaining durable viral suppression.

ViiV also presented findings from the phase I CAB ULA 012 study, which explores dose selection for ultra-long-acting cabotegravir to support administration every four months for HIV prevention. These data mark an important step toward broadening prevention choices and building on the established profile of long-acting cabotegravir in pre-exposure prophylaxis.

Taken together, the presentations at CROI 2026 provided an update on the direction of travel for ViiV Healthcare’s research pipeline. The mix of early-phase and longer-term data on integrase inhibitors, capsid inhibitors and antibody-based combinations offers a snapshot of how extended-interval dosing strategies are progressing, as researchers assess their safety, durability and practical application in HIV treatment and prevention.